iShares Nasdaq U.S. Biotech UCITS ETF

The iShares Nasdaq U.S. Biotech UCITS ETF is an exchange-traded fund designed to track the performance of the Nasdaq Biotechnology Index, providing targeted exposure to the U.S. biotechnology and pharmaceutical sectors. This fund invests in a diverse range of publicly listed companies at the forefront of biomedical research and development, encompassing large, mid, and small-cap firms. Its portfolio includes innovators in genetic engineering, pharmaceuticals, and biotechnology—industries integral to advancing treatments, therapies, and cures for various human diseases. Managed by BlackRock, the ETF employs a physical replication strategy, using a representative sampling technique to mirror the underlying index. Launched in 2017 and domiciled in Ireland, it features an accumulating structure, meaning any dividends earned are reinvested into the fund, not distributed as payouts. With a competitively low total expense ratio, the iShares Nasdaq U.S. Biotech UCITS ETF offers investors efficient diversification across a dynamic sector that sits at the nexus of healthcare innovation and technology, playing a significant role in the evolving landscape of global health markets.